At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALLK Allakos Inc.
Market Closed 06-28 16:00:00 EDT
1.00
-0.06
-5.66%
盘后0.9900
-0.01-1.00%
19:58 EDT
High1.06
Low0.9348
Vol8.55M
Open1.06
D1 Closing1.06
Amplitude11.81%
Mkt Cap88.54M
Tradable Cap59.17M
Total Shares88.54M
T/O8.56M
T/O Rate14.46%
Tradable Shares59.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Allakos drops after early-stage results for lead asset
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.